Welcome to our dedicated page for Ventas SEC filings (Ticker: VTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ventas, Inc. filings document the regulatory record of a healthcare real estate investment trust whose common stock trades on the New York Stock Exchange under VTR. The company’s disclosures include Form 8-K reports for operating results, quarterly and annual earnings releases, dividend-related events, material financing agreements and capital markets activity.
Recent filings also cover amendments to credit facilities, registered senior notes issued by Ventas Realty, Limited Partnership and guaranteed by Ventas, ATM sales agreement updates, officer-transition disclosures and proxy materials addressing director elections, executive compensation, shareholder voting matters and governance.
Ventas, Inc. is launching an at-the-market equity program for up to $2.5 billion aggregate gross sales price of its common stock. The company can sell shares from time to time through multiple sales agents or directly to them as principal, and may also use forward sale agreements with affiliated banks.
Ventas will receive net cash proceeds from shares it issues and from physical settlement of any forward sales, and plans to use the funds for working capital, acquisitions and investments, or repayment of existing debt. As of February 3, 2026, Ventas had 474,965,224 common shares outstanding.
Ventas, Inc. insider plans a new stock sale after recent transactions. A Form 144 notice reports a proposed sale of 10,322 shares of Ventas common stock through Merrill Lynch on the NYSE, with an indicated aggregate market value of $848,751.37 and 469,732,824 shares outstanding.
The shares to be sold were acquired on 02/06/2026 via a broker-assisted exercise of employee stock options. Over the prior three months, Debra Cafaro reported several Ventas stock sales, including 41,294 shares on 11/17/2025 and three separate 10,322-share transactions, with disclosed gross proceeds for each sale.
Ventas, Inc. is an S&P 500 healthcare REIT focused on senior housing, outpatient medical buildings, research centers, hospitals and other healthcare assets in North America and the U.K. As of December 31, 2025, it owned or had investments in 1,409 properties, including 1,374 segment properties.
The company operates through three main segments: senior housing operating (SHOP), outpatient medical and research (&R) and triple-net leased (NNN). For 2025, total NOI was $2.39 billion, with SHOP contributing $1.18 billion (49.4%), &R $590 million (24.7%) and NNN $588 million (24.6%). Non-segment activities added $30.7 million.
Ventas highlights concentration risk with key managers and tenants such as Atria, Sunrise, Le Groupe Maurice, Brookdale, Kindred and Ardent, and outlines extensive regulatory, reimbursement, macroeconomic, labor and REIT qualification risks. At June 30, 2025, its public float was valued at $28.6 billion, and 474,965,224 common shares were outstanding as of February 3, 2026.
Ventas, Inc. reported strong fourth quarter and full-year 2025 results driven by its senior housing portfolio and announced an 8% dividend increase. In Q4 2025, net income attributable to common stockholders was $0.15 per share, while Nareit FFO was $0.91 and Normalized FFO was $0.89 per share, up 10% from 2024. For 2025, net income per share rose to $0.54, with Nareit FFO of $3.50 and Normalized FFO of $3.48 per share, reflecting 11% and 9% growth, respectively. Same-store Cash NOI grew 8% for the year, with the SHOP segment exceeding 15% growth, supported by higher occupancy and rate gains. Ventas completed $2.5 billion of senior housing investments in 2025, raised $3.2 billion of equity, and ended the year with $5.3 billion of liquidity and Net Debt-to-Further Adjusted EBITDA of 5.2x. The quarterly dividend was raised to $0.52 per share, payable April 16, 2026. For 2026, the company guides to midpoints of $0.57 in net income per share, $3.68 in Nareit FFO per share, and $3.83 in Normalized FFO per share, implying 8% year-over-year Normalized FFO growth on a comparable basis.
Ventas, Inc. executive Carey S. Roberts, EVP and General Counsel, reported routine tax-related share withholdings on February 1, 2026. Three Form 4 transactions, all coded "F", reflect common shares withheld to pay taxes upon vesting of restricted stock units granted under the Ventas, Inc. 2022 Incentive Plan.
The transactions covered 2,239, 2,245, and 2,270 shares of common stock at a reference price of $77.67 per share, with ownership remaining directly held. After these withholdings, Roberts continued to beneficially own over one hundred thousand shares of Ventas common stock.
Ventas, Inc. executive vice president and CFO Robert F. Probst reported routine share withholdings related to restricted stock unit vesting on February 1, 2026. A total of 3,244, 3,252, and 3,704 shares of common stock were withheld at a price of $77.67 per share to cover taxes on RSUs granted in 2023, 2024, and 2025 under the Ventas, Inc. 2022 Incentive Plan. After these tax-withholding transactions, he beneficially owned 125,959 shares of Ventas common stock directly.
Ventas, Inc. executive James Justin Hutchens reported share withholding transactions tied to restricted stock vesting. On February 1, 2026, a total of 2,894, 3,046, and 3,643 shares of common stock were withheld to pay taxes on vested restricted stock units granted in 2023, 2024, and 2025 under the Ventas, Inc. 2022 Incentive Plan, at a reference price of $77.67 per share. After these tax withholdings, Hutchens directly beneficially owned 157,466 shares of Ventas common stock.
Ventas, Inc. Chairman and CEO Debra A. Cafaro reported several equity transactions in early February 2026. On February 1, 2026, shares of common stock (7,668, 7,686 and 8,407) were withheld at $77.67 per share to cover taxes on vested restricted stock units from grants made in 2023, 2024 and 2025.
On February 2, 2026, she exercised 10,322 stock options at an exercise price of $73.71 per share, from options that were fully vested and scheduled to expire on August 3, 2026. The same day, 10,322 shares of common stock were sold at a weighted average price of $77.6599 per share under a Rule 10b5-1 trading plan established on March 28, 2024.
After these transactions, Cafaro directly beneficially owned 1,114,034 shares of Ventas common stock and held 10,322 unexercised stock options.
Ventas, Inc. executive Peter J. Bulgarelli reported tax‑related share withholdings tied to equity vesting. On February 1, 2026, three Form 4 transactions (code F) show a total of 7,058 shares of common stock withheld at $77.67 per share to cover taxes on restricted stock units granted in 2023, 2024, and 2025 under the Ventas, Inc. 2022 Incentive Plan. After these withholding events, he directly held 97,754 shares of Ventas common stock.
Ventas, Inc. insider Debra Cafaro has filed a Form 144 to sell 10,322 shares of Ventas common stock. The shares are to be sold through Merrill Lynch on the NYSE, with an aggregate market value of $801,605.71 and 469,732,824 Ventas shares outstanding.
The 10,322 shares come from a broker-assisted exercise of employee stock options on 02/02/2026, with acquisition and payment occurring the same day. Over the prior three months, Cafaro reported multiple Ventas stock sales totaling several hundred thousand shares and generating tens of millions of dollars in gross proceeds.